36 results about "Human hepatitis B virus" patented technology

The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

The disclosure is directed to methods, kits, and compositions, for amplifying and detecting a human hepatitis B virus (HBV) in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes.

The present invention provides a hepatitis B virus isolate named as the surface antigen of human hepatitis B virus-'S'-145 Singapore strain (change glycine to arginine), and the virus genome composed of it has been obtained in December, 1997 It was preserved in the European Cell Culture Collection on the 15th, with the registration numbers P97121504, P97121505 and P97121506. The present invention also provides isolated nucleic acids and purified peptides encoding a polypeptide, wherein said polypeptide is a mutant major surface antigen of a hepatitis B virus strain, said polypeptide having an amino acid sequence similar to that of wild-type hepatitis B virus The amino acid sequence of the major surface antigen of said polypeptide differs in that the amino acid at position 145 of said polypeptide is arginine instead of glycine. The present invention further provides an isolated nucleic acid encoding a peptide encoded by a nucleic acid molecule comprising nucleotides 527 to 595 of SEQ ID NO:1, and purified peptides thereof. The invention also provides various methods of using the disclosed isolated nucleic acids and polypeptides. The present invention also provides various applications of said virus strain and its protein.

The invention relates to a recombinant vector for the human hepatitis B virus, belonging to the fields of biological medicine and genetic engineering. Compared with a wild human hepatitis B virus, viral genome involved in the invention lacks a part of a spacer region or the whole spacer region of hepatitis B virus polymerase and a part of a core protein and has a ribosome entry site inserted before the initiation codon of the polymerase. The invention also provides a preparation method for the recombinant vector and application of the recombinant vector to gene therapy targeting to the liver or hepatocytes. The recombinant vector for the human hepatitis B virus provided by the invention supports insertion of a plurality of exogenous sequences and gene expression. A recombinant hepatitis B virus does not have genome replication capability, but recombinant hepatitis B virus genome can realize high-efficiency replication under the condition of supply of the core protein, and packages and secretes infectious intact recombinant hepatitis B virus particles under the condition of simultaneous supply of the core protein and surface protein; so it is proved that the recombinant vector for the human hepatitis B virus provided by the invention has good application prospects as a liver-specific gene introduction vector.

The invention provides a small interference RNA molecule SiRNA capable of attacking human hepatitis B virus, which is double chain RNA molecule whose sequence has at least 70% of consanguinity degree with the sequence (I), wherein the antisense chain of the sequence (I) and one nucleic acid mutant has no consanguinity with the known human gene and gene expression segment. The SiRNA can be used for preparing medicament or preparation for prevention or treating hepatitis B and any diseases relating to hepatitis B viral infection.

The invention relates to the technical field of genetic engineering, and particularly relates to a guide RNA (gRNA) sequence based on a CRISPR / Cas9 system and combinations thereof, as well as gRNA for a specific targeted knockout hepatitis B virus cccDNA P gene. In the invention, 30 gRNAs are designed according to design principles of CRISPR / Cas9, have a sequence table as shown in SEQ ID NO.1-30, and are constructed on a PX458 vector, to screen out four more efficient gRNAs. The CRISPR / Cas9 system guided by the four gRNAs and combinations thereof is utilized in a human hepatocellular carcinoma cell line (HepG2.2.15) to effectively knock out the human hepatitis B virus cccDNA P gene. The gRNA of the specific targeted hepatitis B virus cccDNA prepared in the invention can accurately target the hepatitis B virus cccDNA and realize gene knockout. The preparation method is simple in operation; the gRNA has a good targeting property; the CRISPR / Cas9 system is high in knockout efficiency.

The invention belongs to the field of biotechnology and genetic engineering, and relates to a method for evaluating an X protein (HBx protein) binding molecule of human hepatitis C virus. The method provided by the invention comprises the following steps: expressing a secreting type fusion protein containing the HBx protein and luciferase NanoLuciferase (Nluc) in a cell; and quantifying the levelof the secreted HBx protein by detecting the activity of luciferase of the fusion protein. The method can be used for screening and identifying the HBx protein binding molecule, provides a support forresearching an HBx protein targeted drug, and has good application prospect.

The disclosure is directed to methods, kits, and compositions, for amplifying and detecting a human hepatitis B virus (HBV) in a sample, which comprises a variety of combinations of forward oligonucleotide primers, reverse oligonucleotide primers, and oligonucleotide probes.

The invention belongs to the biomedicine field, and relates to a short peptide for inhibiting human hepatitis B virus infection. The short peptide comprises anyone of the following amino acid sequences: 1, N-leucine-arginine-asparagine-isoleucine-arginine-C; 2, an amino acid sequence obtained through deleting one or two amino acids from the above amino acid sequence 1 and capable of inhibiting the human hepatitis B virus infection; 3, an amino acid sequence obtained through substituting one or two amino acids in the amino acid sequence 1 and capable of inhibiting the human hepatitis B virus infection; 4, adding one or more amino acids to the amino acid sequence 1 and capable of inhibiting the human hepatitis B virus infection; and 5, an amino acid sequence obtained through repeated splicing of the amino acid sequences 1-4 and capable of inhibiting the human hepatitis B virus infection. The invention also provides a construct and a cell of an amino acid sequence comprising the short peptide or of a nucleic acid coding sequence of the short peptide, and an application of the short peptide.

The present invention relates to primer sets and / or probes for the specific detection of human hepatitis B virus (HBV). The present invention also relates to kits and microarrays for specific detection of human hepatitis B virus comprising primer sets and / or probes. The present invention also relates to the use of primer sets and / or probes in the preparation of kits and microarrays for specific detection of hepatitis B virus in samples. The present invention also relates to a method for detecting HBV genes in samples using primer sets and / or probes.

The present invention provides an in vitro activity test of human hepatitis B virus (HBV) DNA polymerase, which comprises utilizing an oligonucleotide incorporated into the SP6 viral promoter as a 5' oligonucleotide to amplify HBV from a sample by PCR DNA polymerase, direct transcription and translation of the PCR product in the presence of a radiolabeled reagent, and determination of HBV DNA polymerase priming. The present invention also provides the application of such a test in the activity test of various serum samples, in the screening of HBV DNA polymerase inhibitors, and in the detection and / or screening of potential anti-HBV drugs on human HBV DNA polymerization Applications in the inhibitory capacity of DNA-priming activity of enzymes.

The invention provides a specific sgRNA combined with an immunogene to inhibit HBV replication, an expression vector thereof, and an application of the specific sgRNA and the expression vector. The sgRNA sequences of a human hepatitis B virogene suitable for CRISPR-Cas9 targeting editing and a PD-1 gene are designed, the plasmid vector of the sgRNA inhibiting HBV and PD-1 genes is constructed, and the plasmid vector and a nuclease gene expression vector are transferred to HBV transgenic mice, and can obviously inhibit HBV DNA replication. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, and high CRISPR-Cas9 knockout efficiency. The sgRNAs specifically targeting the HBV and PD-1 genes can accurately splice the HBV and PD-1 genes, inhibit in vivo hepatitis B virus replication, and reduce the hepatitis B virus antigen expression.